VivoSeq
Other

Ventricular Septal Defect

3

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Ventricular Septal Defect is an early-stage landscape with 3 programs across 3 companies. The most active players are Asklepion Pharmaceuticals, LLC, Milestone Pharmaceuticals Inc., Leadiant Biosciences, Inc.. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Asklepion Pharmaceuticals, LLC

1 program

Phase 1M

Milestone Pharmaceuticals Inc.

1 program

ApprovedL

Leadiant Biosciences, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

Use of TEE Derived Measurement vs Direct Measurement Under General Anesthesia in Assessment of Pressure Gradient in Peri Membranous Ventricular Septal Defect
Not yet recruiting·AAin Shams University·N/A·NCT07623330·115 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)